https://www.bioworld.com/rss en-us The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million. http://www.bioworld.com/articles/727983 Tue, 13 Jan 2026 00:00:00 -0500 https://www.bioworld.com/articles/727983-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025 Nonprofit stamp The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127.43 million in 2025 after exceeding $21.4 billion in 2021. The 2025 total also represents a steep drop from 2024’s $754.56 million. http://www.bioworld.com/articles/727764 Thu, 08 Jan 2026 12:00:00 -0500 https://www.bioworld.com/articles/727764-pandemic-era-nonprofit-funding-fades-from-biopharma-in-2025 Nonprofit stamp Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter. http://www.bioworld.com/articles/725899 Tue, 04 Nov 2025 10:00:00 -0500 https://www.bioworld.com/articles/725899-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal Nonprofit stamp Biopharma partnerships involving nonprofits have declined sharply since peaking during the pandemic. Deal value surged from $5.18 billion in 2019 to $21.44 billion in 2021, driven by COVID-19 collaborations and vaccine-related funding, before falling to $7.99 billion in 2022 and $754.6 million in 2024. So far in 2025, nonprofit deal value totals $126 million through the third quarter. http://www.bioworld.com/articles/725777 Mon, 03 Nov 2025 10:00:00 -0500 https://www.bioworld.com/articles/725777-biopharma-nonprofit-dealmaking-and-grants-stabilize-in-a-new-normal Nonprofit stamp Nonprofit dealmaking in biopharma has been limited in 2025, with total disclosed value reaching just $99.7 million through July. Nearly all of that came in January, when deals totaled $96.9 million. After a quiet first quarter, modest activity resumed with $1.4 million in April and $1.6 million in July, while the other months saw no reported nonprofit partnerships. http://www.bioworld.com/articles/722754 Fri, 01 Aug 2025 11:00:00 -0400 https://www.bioworld.com/articles/722754-nih-leads-grant-funding-as-awards-top-11b-in-2025 Nonprofit stamp Biopharma nonprofit deals remained low in 2024, compared to the pandemic and pre-pandemic years, while grants saw a slight decline from the previous year. http://www.bioworld.com/articles/716871 Fri, 31 Jan 2025 12:00:00 -0500 https://www.bioworld.com/articles/716871-2024-nonprofit-deals-plummet-from-pandemic-peak Nonprofit stamp Through September 2024, biopharma firms secured $720.56 million in nonprofit deals, up in value through July and also marking a 21% rise from the $593.23 million in the first three quarters of 2023, though still falling short of 2019-2022 levels. Grants saw an even sharper surge, jumping 131% year-over-year from $1.66 billion to $3.84 billion in the same period, falling short only of 2020 in value. http://www.bioworld.com/articles/714124 Fri, 01 Nov 2024 12:00:00 -0400 https://www.bioworld.com/articles/714124-steady-gains-in-biopharma-deals-as-grants-see-sharp-year-over-year-increase Nonprofit stamp Through July 2024, biopharma firms received $2.52 billion in grants, marking a 52% increase from $1.66 billion in grants during the same period last year. However, nonprofit deals are at their lowest level on record, according to BioWorld’s records. Although nonprofit deal values were initially higher in April compared to 2023, they have since dropped and are now well below the levels seen in prior years. BioWorld’s records. Although nonprofit deal values were initially higher in April compared to 2023, they have since dropped and are now well below the levels seen in prior years.]]> http://www.bioworld.com/articles/712163 Fri, 30 Aug 2024 12:00:00 -0400 https://www.bioworld.com/articles/712163-biopharma-grants-reach-four-year-high-of-25b-nonprofit-deals-down Nonprofit stamp Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value. http://www.bioworld.com/articles/703464 Tue, 05 Dec 2023 12:00:00 -0500 https://www.bioworld.com/articles/703464-biopharma-grants-see-75-growth-yoy-while-nonprofit-deals-decline Nonprofit stamp Biopharma grants have sustained the upward trajectory noted in August, ending October up nearly 75% compared to the corresponding period last year. In contrast, nonprofit deal value has continued its year-over-year decline, marked by a more than 90% decrease in value. http://www.bioworld.com/articles/703424 Fri, 01 Dec 2023 12:00:00 -0500 https://www.bioworld.com/articles/703424-biopharma-grants-see-75-growth-yoy-while-nonprofit-deals-decline Nonprofit stamp Biopharma grants are up nearly 150% compared to the same time period last year, largely due to a number of $100 million-plus grants from the Biomedical Advanced Research and Development Authority (BARDA). Meanwhile, nonprofit deal value has declined year-over-year, with the number of transactions down 42.21%. http://www.bioworld.com/articles/700664 Tue, 05 Sep 2023 12:00:00 -0400 https://www.bioworld.com/articles/700664-biopharmas-receive-143b-in-barda-grants-in-2023 Nonprofit stamp As the biopharma industry moves away from the COVID-19 pandemic and expands research in other areas, the amount of money flowing into companies through deals with nonprofit or government entities and grants has plummeted 53% in comparison with 2021. The drop is mainly due to a diminishing number and a lower overall value of bio/nonprofit partnerships. Grants, on the other hand, have risen in both areas. http://www.bioworld.com/articles/692802 Tue, 27 Dec 2022 12:00:00 -0500 https://www.bioworld.com/articles/692802-bio-nonprofit-deals-slow-as-grants-pick-up-in-second-half-of-2022 Nonprofit stamp The number of biopharma deals with nonprofit or government entities has dwindled in recent months, while industry grants are climbing. Combined, however, a total of 936 bio/nonprofit deals and grants worth $11.17 billion is down by 37% in comparison with last year’s $17.8 billion and by 58.7% in comparison with 2020’s $27 billion. The volume also is down significantly by 16.8% from 2021 and by 33.4% from 2020. http://www.bioworld.com/articles/691625 Tue, 15 Nov 2022 12:00:00 -0500 https://www.bioworld.com/articles/691625-bio-nonprofit-deals-slow-grants-pick-up-in-2022s-second-half Nonprofit stamp While biopharma grants and company deals with nonprofits and government entities have dropped below each of the last two years, the volume of activity for non-pandemic-related efforts has remained steady. A total of 837 biopharma-nonprofit deals and grants combined so far this year are worth $10.8 billion, which is down by 21.6% over last year’s $13.7 billion and by 15.6% over 2021’s 992 volume. Also down are the deals and grants focused on the COVID-19 pandemic. http://www.bioworld.com/articles/690624 Fri, 14 Oct 2022 12:00:00 -0400 https://www.bioworld.com/articles/690624-bio-nonprofit-deal-and-grant-value-of-108b-down-by-22 Red arrow down on money background As the COVID-19 pandemic continues to wind down, the value of biopharma company deals with nonprofit and government entities, as well as grants, are down nearly 64%. Through mid-May 2022, BioWorld has tracked 309 bio/nonprofit deals worth $1.12 billion, and a total of 129 grants valued at $505.85 million. BioWorld has tracked 309 bio/nonprofit deals worth $1.12 billion, and a total of 129 grants valued at $505.85 million.]]> http://www.bioworld.com/articles/519118 Tue, 24 May 2022 12:00:00 -0400 https://www.bioworld.com/articles/519118-biopharma-grant-and-nonprofit-deal-values-plunge Gold coins and red down arrow The number of biopharma deals with nonprofits or government entities has dropped over last year, partly due to fewer COVID-19-related alliances, but the activity in 2022 is still strong in comparison to pre-pandemic years. http://www.bioworld.com/articles/516078 Tue, 15 Feb 2022 12:00:00 -0500 https://www.bioworld.com/articles/516078-nonprofit-deal-and-grant-activity-focused-on-pandemic-falls-by-68 Nonprofit stamp Similar to 2020, the COVID-19 pandemic has dominated both biopharma deals with nonprofit entities and grants in 2021. Combined, pandemic deals and grants account for 87% of the total value, but only 22% of the volume, for the year. Through the week of Christmas, BioWorld has recorded 388 grants for the industry, valued at $2.94 billion, and 845 bio/nonprofit deals worth $21.44 billion. Of those, 82 grants worth $1.4 billion and 194 deals worth $19.8 billion involved therapeutic and vaccine development or supply agreements for COVID-19. BioWorld has recorded 388 grants for the industry, valued at $2.94 billion, and 845 bio/nonprofit deals worth $21.44 billion. Of those, 82 grants worth $1.4 billion and 194 deals worth $19.8 billion involved therapeutic and vaccine development or supply agreements for COVID-19.]]> http://www.bioworld.com/articles/514677 Wed, 29 Dec 2021 12:00:00 -0500 https://www.bioworld.com/articles/514677-top-10-nonprofit-deals-all-for-covid-19-primarily-us-government-pacts Women handshake with virology graphics On target with last year, a total of 87% of funds recorded in 2021 through biopharma collaborations with nonprofit entities by the end of October are focused on COVID-19 pandemic efforts. The pandemic accounts for 54% of the money collected through grants, which is still a sturdy amount but down from 76% in 2020. http://www.bioworld.com/articles/512888 Fri, 29 Oct 2021 12:00:00 -0400 https://www.bioworld.com/articles/512888-covid-19-still-accounts-for-bulk-of-nonprofit-deals-and-grants Coronavirus and coins Biopharma company deals with nonprofit entities, as well as grants, are not keeping the same pace as last year, but the proportion of money flowing into COVID-19 efforts continues to account for the majority of those recorded overall. http://www.bioworld.com/articles/510762 Tue, 24 Aug 2021 12:00:00 -0400 https://www.bioworld.com/articles/510762-slipping-behind-last-year-nonprofit-deals-and-grants-still-driven-by-covid-19 Nonprofit stamp Although more than a third of U.S. citizens are fully vaccinated from COVID-19 and society moves closer to normalcy in many parts of the world, the SARS-CoV-2 virus continues to dramatically impact biopharma dealmaking with nonprofit entities, as well as grant awards. http://www.bioworld.com/articles/507274 Wed, 19 May 2021 12:00:00 -0400 https://www.bioworld.com/articles/507274-pandemic-efforts-dominate-with-76-of-the-nonprofit-deal-and-grant-value Nonprofit stamp Busting a logjam of inadequate data sharing methods and communications between pharmas and health authorities around the world is the impetus behind the creation of nonprofit Accumulus Synergy Inc., whose common, cloud-based platform is designed to make the regulatory process easier for everyone involved. The coalition’s initial membership is a Who’s Who of big pharma: Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Glaxosmithkline plc, the Janssen Pharmaceutical Cos. of Johnson & Johnson, Eli Lilly and Co., Pfizer Inc., Roche Holding AG, Sanofi SA and Takeda Pharmaceutical Co. Ltd. http://www.bioworld.com/articles/502727 Fri, 22 Jan 2021 12:00:00 -0500 https://www.bioworld.com/articles/502727-accumulus-collaborators-plan-to-streamline-data-sharing-and-communications Cloud data sharing illustration The amount of money flowing into the biopharma industry via grants and collaborations with nonprofit and government entities is a 272% increase over last year, with efforts to fight the COVID-19 pandemic accounting for 84% of the total for 2020. http://www.bioworld.com/articles/501858 Tue, 29 Dec 2020 12:00:00 -0500 https://www.bioworld.com/articles/501858-us-government-responsible-for-68-of-biopharmas-nonprofit-and-grant-funding-in-2020 U.S. flag and money The combined total of biopharma nonprofit collaborations and grants in 2020 has reached about $24 billion, more than three times the amount recorded for 2019. http://www.bioworld.com/articles/500642 Wed, 25 Nov 2020 12:00:00 -0500 https://www.bioworld.com/articles/500642-biopharma-nonprofitgrant-deals-triple-that-of-2019 Nonprofit stamp Without the COVID-19 pandemic, projected values of biopharma nonprofit collaborations and grants would be 72% and 30% below last year’s levels, although it is impossible to know what deals may have come to fruition in a world absent of the disruptive SARS-CoV-2 virus. http://www.bioworld.com/articles/498215 Fri, 25 Sep 2020 12:00:00 -0400 https://www.bioworld.com/articles/498215-pandemic-accounts-for-86-of-nonprofit-deals-and-grants-in-2020 Nonprofit stamp